Attention-deficit/hyperactivity disorder is a neurodevelopmental condition affecting both children and adults, with an estimated global prevalence of 5–7%. Core symptoms of inattention, hyperactivity, and impulsivity carry substantial educational, occupational, and quality-of-life burdens. The treatment landscape encompasses stimulant and non-stimulant pharmacotherapy, behavioural interventions, and growing interest in digital therapeutics.
The Benadryl Challenge: Why public health officials are struggling to stop this deadly trend
Public health officials are deploying multi-pronged strategies to combat the Benadryl Challenge, a viral social media trend linked to severe diphenhydramine toxicity and fatalities.
Why prescribed cannabis isn't safer for adolescent brains
Medical cannabis use in adolescents carries significant risks, including psychiatric disorders and impaired neurodevelopment, demanding careful clinical consideration.
ADHD Management: Multimodal Care, Precision Prescribing Supported
Recent evidence supports a multimodal, pragmatic approach to ADHD in children and adolescents, emphasizing individualized care and precision prescribing.
• Aug 28 – 31ERS 2026 • Barcelona, ES 
• Sep 5 – 9EASD 2026 • Milan, IT 
• Sep 28 – Oct 2UEG Week 2026 • Vienna, AT 
• Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA 
• Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US 
• Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12ESC 2026 • Munich, DE • Aug 28 – 31ERS 2026 • Barcelona, ES • Sep 5 – 9EASD 2026 • Milan, IT • Sep 28 – Oct 2UEG Week 2026 • Vienna, AT • Oct 3 – 7Joint ACTRIMS-ECTRIMS 2026 • Toronto, CA • Oct 21 – 23ESMO 2026 • Madrid, ES • Oct 23 – 27AHA 2026 • Chicago, US • Nov 7 – 9ACR 2026 • Washington DC, US • Nov 14 – 19ASH 2026 • New Orleans, US • Dec 12 – 15ACC.27 Together With WCC • Houston, US • Apr 10 – 12